Evidence map›Paper›PMID 26552000›Full record

ArticleVaccine2015

Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice.

Zhenhai Chen, Tuhina Gupta, Pei Xu, Shannon Phan, Adrian Pickar, Wilson Yau, Russell K Karls, Frederick D Quinn, Kaori Sakamoto, Biao He

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhenhai ChenDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Tuhina GuptaDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Pei XuDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Shannon PhanDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Adrian PickarDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Wilson YauDepartment of Pathology, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Russell K KarlsDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Frederick D QuinnDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Kaori SakamotoDepartment of Pathology, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
Biao HeDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA. Electronic address: bhe@uga.edu.
Georgia College & State University · USUniversity of Georgia · US

Funding

A Novel Approach for Mycobacterium Tuberculosis Vaccine DevelopmentR21AI103575 · NIAID · UNIVERSITY OF GEORGIA · PI HE, BIAO · 2013 to 2014
$397k
NIAID NIH HHS R21 AI103575NIAID NIH HHS R21AI103575
6 · The paper itself

Abstract

Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), is an important human pathogen. Bacillus Calmette-Guérin (BCG), a live, attenuated variant of Mycobacterium bovis, is currently the only available TB vaccine despite its low efficacy against the infectious pulmonary form of the disease in adults. Thus, a more-effective TB vaccine is needed. Parainfluenza virus 5 (PIV5), a paramyxovirus, has several characteristics that make it an attractive vaccine vector. It is safe, inexpensive to produce, and has been previously shown to be efficacious as the backbone of vaccines for influenza, rabies, and respiratory syncytial virus. In this work, recombinant PIV5 expressing M. tuberculosis antigens 85A (PIV5-85A) and 85B (PIV5-85B) have been generated and their immunogenicity and protective efficacy evaluated in a mouse aerosol infection model. In a long-term protection study, a single dose of PIV5-85A was found to be most effective in reducing M. tuberculosis colony forming units (CFU) in lungs when compared to unvaccinated, whereas the BCG vaccinated animals had similar numbers of CFUs to unvaccinated animals. BCG-prime followed by a PIV5-85A or PIV5-85B boost produced better outcomes highlighted by close to three-log units lower lung CFUs compared to PBS. The results indicate that PIV5-based M. tuberculosis vaccines are promising candidates for further development.

Indexed as

Drug CarriersAcyltransferasesAnimalsAntigens, BacterialBacterial ProteinsColony Count, MicrobialDisease Models, AnimalFemaleLungMice, Inbred BALB CParainfluenza Virus 5Treatment OutcomeTuberculosisTuberculosis VaccinesVaccines, SyntheticAcyltransferasesantigen 85A, Mycobacterium tuberculosisantigen 85B, Mycobacterium tuberculosisAntigens, BacterialBacterial ProteinsDrug CarriersTuberculosis VaccinesVaccines, SyntheticAntigen 85AAntigen 85BBCGMycobacteria tuberculosisParainfluenza virus 5Vaccine

Identifiers

PMID26552000
PMCPMC5785232
OpenAlexW2144422243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.